Yuemin Nan

Hepatology — Third Hospital of Hebei Medical University, China

LeadR Profile

1 037 ScienceLeadR Reputation 1037
Network Map

Hepatology

Subspecialties: Gastroenterology - Oncology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026

Source: PubMed

Third Hospital of Hebei Medical University

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
From bystander to key player: The mechanisms and therapeutic potential of IL-24 in liver diseases.
liver diseases, cytokines, cells, molecular biology, stress, physiological, neoplasms, liver, research, therapeutics
Mol Biol Rep20260
Evaluation of the Safety and Efficacy of SOF/VEL Treatment and Pre-treatment of TAF in Patients with Chronic Hepatitis B Virus/Hepatitis C Virus Coinfection: A Multicenter Study.
hepatitis c, safety, hepatitis b virus, fibrosis, aspartate aminotransferases, coinfection, hepatitis, chronic, transaminases, liver, herpesvirus 1, cercopithecine, sustained virologic response, viruses, hepatitis viruses, therapeutics, blood platelets, hepatitis b, hepatitis b, chronic, infections, hepatitis
J Clin Transl Hepatol20260
Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
liver diseases, thrombopoietin, platelet count, hematology, safety, liver, drug-related side effects and adverse reactions, platelet transfusion, therapeutics, blood platelets, thrombocytopenia
Am J Hematol20260
Development of anticirrhotic drugs from the perspective of the fatty acid metabolism-immune axis: Taking Fuzheng Huayu tablet as an example.
liver diseases, pharmaceutical preparations, tablets, fatty acids
Hepatobiliary Pancreat Dis Int20260
[Analyzing research advances in single-cell sequencing technology for immunopathological mechanisms in acute-on-chronic liver failure].
liver diseases, cells, genes, acute-on-chronic liver failure, liver, research, therapeutics, liver failure
Zhonghua Gan Zang Bing Za Zhi20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

N/A 5
Phase 3 3

By status:

Recruiting 4
Completed 2
Active not recruiting 1
Unknown 1

By type:

Observational 5
Interventional 3

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic
Phase 3Recruiting2025
Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma
NCT06272656 — carcinoma, hepatocellular, neoplasms, liver, liver neoplasms, therapeutics, carcinoma
N/ARecruiting2024
Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH)
NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide
Phase 3Active not recruiting2021

LeadR Networks

Main global connection map